MGMT promoter methylation status in brain metastases from colorectal cancer and corresponding primary tumors

Future Oncology

Volumn 11, Issue 8, 2015, Pages 1201-1209

  De Maglio, Giovanna ^a   Casagrande, Mariaelena ^a   Guardascione, Michela ^a   Fontanella, Caterina ^a   Lutrino, Stefania Eufemia ^a   Rihawi, Karim ^a   Pisa, Federica Edith ^a   Tuniz, Francesco ^a   Fasola, Gianpiero ^a   Pizzolitto, Stefano ^a   Aprile, Giuseppe ^a  

^a UNIVERSITY HOSPITAL OF UDINE   (Italy)

Author keywords

brain metastases; colorectal cancer; epigenetic; MGMT; pyrosequencing

Indexed keywords

METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; DNA LIGASE; DNA METHYLTRANSFERASE; MGMT PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; BRAIN SURGERY; CANCER PATIENT; COLORECTAL CANCER; CRANIOTOMY; ELECTRONIC MEDICAL RECORD; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROSURGERY; PALLIATIVE THERAPY; PRIMARY TUMOR; PRIORITY JOURNAL; PROMOTER REGION; PYROSEQUENCING; RETROSPECTIVE STUDY; BRAIN NEOPLASMS; COLORECTAL TUMOR; CPG ISLAND; DNA METHYLATION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SECONDARY; SURVIVAL RATE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; COLORECTAL NEOPLASMS; CPG ISLANDS; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROMOTER REGIONS, GENETIC; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEINS;

EID: 84926451598     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.15.2     Document Type: Article

References (30)

1. Gerson SL. Clinical relevance of MGMT in the treatment of cancer. J. Clin. Oncol. 20(9), 2388-2399 (2002).
2. Hegi ME, Sciuscio D, Murat A, Levivier M, Stupp R. Epigenetic deregulation of DNA repair and its potential for therapy. Clin. Cancer Res. 15(16), 5026-5031 (2009).
3. Hegi ME, Diserens AC, Gorlia T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352(10), 997-1003 (2005).
4. Dunn J, Baborie A, Alam F et al. Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy. Br. J. Cancer 101(1), 124-131 (2009).
5. Quillien V, Lavenu A, Karayan-Tapon L et al. Comparative assessment of 5 methods (methylation-specificpolymerasechainreacti on, methylight, pyrosequencing, methylation-sensitive high-resolutionmelting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer 118, 4201-4211 (2012).
6. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 59(4), 793-797 (1999).
7. Brabender J, Usadel H, Metzger R et al. Quantitative O(6)-methylguanine DNA methyltransferase methylation analysis in curatively resected non-small cell lung cancer: associations with clinical outcome. Clin. Cancer Res. 9(1), 223-227 (2003).
8. Pulling LC, Divine KK, Klinge DM et al. Promoter hypermethylation of the O6- methylguanine-DNA methyltransferase gene: more common in lung adenocarcinomas from never-smokers than smokers and associated with tumor progression. Cancer Res. 63(16), 4842-4848 (2003).
9. Zuo C, Ai L, Ratliff P et al. O6- methylguanine-DNA methyltransferase gene: epigenetic silencing and prognostic value in head and neck squamous cell carcinoma. Cancer Epidemiol. Biomarkers Prev. 13(6), 967-975 (2004).
10. Zhang L, Lu W, Miao X, Xing D, Tan W, Lin D. Inactivation of DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation and its relation to p53 mutations in esophageal squamous cell carcinoma. Carcinogenesis 24(6), 1039-1044 (2003).
11. Fumagalli C1, Pruneri G, Possanzini P et al. Methylation of O6-methylguanine-DNA methyltransferase (MGMT) promoter gene in triple-negative breast cancer patients. Breast Cancer Res. Treat. 134(1), 131-137 (2012).
12. Nagy E, Gajjar KB. Patel II MGMT promoter hypermethylation and K-RAS, PTEN and TP53 mutations in tamoxifen-exposed and non-exposed endometrial cancer cases. Br. J. Cancer 110(12), 2874-2880 (2014).
13. Kim SH, Bae SI, Lee HS, Kim WH. Alteration of O6-methylguanine-DNA methyltransferase in colorectal neoplasms in sporadic and familial adenomatous polyposis patients. Mol. Carcinog. 37(1) 32-38 (2003).
14. Dallol A, Al-Maghrabi J, Buhmeida A et al. Methylation of the polycomb group target genes is a possible biomarker for favorable prognosis in colorectal cancer. Cancer Epidemiol. Biomarkers Prev. 21(11), 2069-2075 (2012).
15. Konishi K, Shen L, Jelinek J et al. Concordant DNA methylation in synchronous colorectal carcinomas. Cancer Prev. Res. (Phila.) 2(9), 814-822 (2009).
16. Esteller M, Toyota M, Sanchez-Cespedes M et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res. 60(9), 2368-2371 (2000).
17. Nagasaka T, Sharp GB, Notohara K et al. Hypermethylation of O6-methylguanine- DNA methyltransferase promoter may predict nonrecurrence after chemotherapy in colorectal cancer cases. Clin. Cancer Res. 9(14), 5306-5312 (2003).
18. Krtolica K, Krajnovic M, Usaj-Knezevic S, Babic D, Jovanovic D, Dimitrijevic B. Comethylation of p16 and MGMT genes in colorectal carcinoma: correlation with clinicopathological features and prognostic value. World J Gastroenterol. 13(8), 1187-1194 (2007).
19. Kim JC, Choi JS, Roh SA, Cho DH, Kim TW, Kim YS. Promoter methylation of specific genes is associated with the phenotype and progression of colorectal adenocarcinomas. Ann. Surg. Oncol. 17(7), 1767-1776 (2010).
20. Shacham-Shmueli E, Beny A, Geva R, Blachar A, Figer A, Aderka D. Response to temozolomide in patients with metastatic colorectal cancer with loss of MGMT expression: a new approach in the era of personalized medicine? J. Clin. Oncol. 29(10), e262-e265 (2011).
21. Hochhauser D, Glynne-Jones R, Potter V et al. A Phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter. Mol. Cancer Ther. 12(5), 809-818 (2013).
22. Amatu A, Sartore-Bianchi A, Moutinho C et al. Promoter CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a Phase II study for metastatic colorectal cancer. Clin. Cancer Res. 19(8), 2265-2272 (2013).
23. Aprile G, Zanon E, Tuniz F et al. Neurosurgical management and postoperative whole-brain radiotherapy for colorectal cancer patients with symptomatic brain metastases. J. Cancer Res. Clin. Oncol. 135(3), 451-457 (2009).
24. Hamilton MG, Roldíín G, Magliocco A, McIntyre JB, Parney I, Easaw JC. Determination of the methylation status of MGMT in different regions within glioblastomamultiforme. J. Neurooncol. 102, 255-260 (2011).
25. Mikeska T1, Felsberg J, Hewitt CA et al. Analysing DNA methylation using bisulphite pyrosequencing. Methods Mol. Biol. 2791, 33-53 (2011).
26. Preusser M, Berghoff AS, Manzl C et al. Clinical Neuropathology practice news 1-2014: pyrosequencing meets clinical and analytical performance criteria for routine testing of MGMT promoter methylation status in glioblastomaclin. Neuropathol. 33(1), 6-14 (2014).
27. Konishi K, Watanabe Y, Shen L et al. DNA methylation profiles of primary colorectal carcinoma and matched liver metastasis. PLoS ONE 6(11), e27889 (2011).
28. Ju HX, An B, Okamoto Y et al. Distinct profiles of epigenetic evolution between colorectal cancers with and without metastasis. Am. J. Pathol. 178(4), 1835-1846 (2011).
29. Shima K, Morikawa T, Baba Y et al. MGMT promoter methylation, loss of expression and prognosis in 855 colorectal cancers. Cancer Causes Control 22(2), 301-309 (2011).
30. Menis J, Fontanella C, Follador A, Fasola G, Aprile G. Brain metastases from gastrointestinal tumours: tailoring the approach to maximize the outcome. Crit. Rev. Oncol. Hematol. 85(1), 32-44 (2013).